Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats

Hypertension

Volumn 30, Issue 6, 1997, Pages 1560-1565

  Henriksen, Erik J ^a   Jacob, Stephan ^b   Fogt, Donovan L ^a   Youngblood, Erik B ^a   Gödicke, Jochen ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Glucose tolerance test; Imidazoline receptor modulation; Sympatholytics

Indexed keywords

ANTIHYPERTENSIVE AGENT; FATTY ACID; IMIDAZOLINE; MOXONIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030708654     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.6.1560     Document Type: Article

References (29)

1. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317: 350-357.
2. Pollare T. Insulin sensitivity and blood lipids during antihypertensive treatment with special reference to ACE inhibition. J Diabetes Complications. 1990;4:75-78.
3. Natali A, Santoro D, Palombo C, Cerri M, Ghione S, Ferrannini E. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension. 1991;17:170-178.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
5. Reaven GM. Role of insulin resistance in human disease (Syndrome X): an expanded definition. Annu Rev Med. 1993;44: 121-131.
6. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
7. Crisp P, Faulds D. Moxonidine: a review of its pharmacology, and its therapeutic use in essential hypertension. Drugs. 1992;44: 993-1012.
8. Ernsberger P, Elliott HL, Weimann H-J, Raap A, Haxhui MA, Hofferber E, Löw-Kröger A, Reid JL, Mest H-J. Moxonidine. A second-generation central antihypertensive agent. Cardiovasc Drug Rev. 1993;11:411-431.
9. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer S, Ziegler D. Effect of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors. 1995; 5(suppl 1):19-27.
10. Ernsperger P, Koletsky RJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardovasc Drugs Ther. 1996;10:275-282.
11. 1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens. 1997;15(suppl 1):S9-S23.
12. Bray G. The Zucker-fatty rat: a review. Fed Proc. 1977;36:148-153.
13. Mathe D. Dyslipidemia and diabetes: animal models. Diabetes Metab Rev. 1995;21:106-111.
14. Cortez MY, Torgan CE, Brozinick JT, Ivy JL. Insulin resistance of obese Zucker rats exercise trained at two different intensities. Am J Physiol. 1991;261:E613-E619.
15. Krebs HA, Henseleit K. Untersuchung über die Harnstoffbildung im Tierkörper. Hoppe-Seyler's Z Physiol Chem. 1932;210:33-66.
16. Henriksen EJ, Ritter LS. Effect of soleus unweighting on stimulation of insulin-independent glucose transport activity. J Appl Physiol. 1993;74:1653-1657.
17. Gulve EA, Henriksen EJ, Rodnick KJ, Youn JH, Holloszy JO. Glucose transporters and glucose transport in skeletal muscles of 1 to 25 month old rats. Am J Physiol. 1993;264:E319-E327.
18. Armah BI, Hofferber E, Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforschung. 1988;38:1426-1434.
19. 1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans. Eur J Pharmacol. 1995;284:199-203.
20. Rösen P, Ohly P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens. 1997;15(suppl 1):S31-S38.
21. Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine-selective stimulation of metabolic alpha-adrenergic pathways. Diabetes 1978; 27:554-562.
22. Nakadate T, Nakaki T, Muraki T, Kato, R. Adrenergic regulation of blood glucose levels: possible involvement of post-synaptic alpha-2-type adrenergic receptors regulating insulin release. J Pharmacol Exp Ther. 1980;215:226-230.
23. DiTullio NW, Cielinski L, Matthews WD, Storer B. Mechanisms involved in the hyperglycemic response induced by clonidine and other alpha-2 adrenoceptor agonists. J Pharmacol Exp Ther. 1984; 228:168-173.
24. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3-10.
25. Ishizuka T, Farrell CJ, Koletsky RJ, Ernsberger P, Bebol D, Friedman JE. Molecular mechanism of insulin resistance in the genetically obese spontaneously hypertensive rat, a model of human Syndrome X (abstract). International Congress of Endocrinology, June 13, 1996.
26. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocrine Rev. 1995;16:117-142.
27. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism. 1995; 44:267-272.
28. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism. 1996;45:535-541.
29. Jacob S, Henriksen EJ, Fogt DL, Dal Ponte D, Dietze GJ. The adrenergic modulator celiprolol reduces insulin resistance in the obese Zucker rat. Diabetologia. 1996;39:289.